Literature DB >> 8834559

Risk factors for vulvovaginal candidiasis: a case-control study among university students.

A M Geiger1, B Foxman.   

Abstract

Vulvovaginal candidiasis (VVC) is a common inflammatory condition caused by vaginal overgrowth of Candida albicans. Typical symptoms include pruritus and discharge. To test the association between several hypothesized risk factors and VVC, we conducted a case-control study among university students, with both clinic and population controls. Symptomatic, culture-proven VVC was associated with receptive oral sex twice or more in the previous 2 weeks [vs not at all, odds ratio (OR) = 3.5; 95% confidence interval (CI) = 1.7-7.0]; oral contraceptive use (OR = 1.8; 95% CI = 0.95-3.6); spermicide use (OR = 3.3; 95% CI = 1.6-6.8); a prior diagnosis of VVC in the previous year (OR = 3.0; 95% CI = 1.5-5.9); and black (OR = 6.8; 95% CI = 3.1-15) and "other" race (OR = 2.2; 95% CI = 1.0-4.6). Estimates are from a cases vs population controls logistic regression model including all five variables; results for cases vs clinic controls were similar. After adjusting for these factors, many other hypothesized risk factors, such as antibiotic use, menstrual hygiene practices, and vaginal intercourse, had little association with VVC.

Entities:  

Mesh:

Year:  1996        PMID: 8834559     DOI: 10.1097/00001648-199603000-00013

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  23 in total

Review 1.  Vulvovaginitis Caused by Candida Species Following Antibiotic Exposure.

Authors:  Asmita Shukla; J D Sobel
Journal:  Curr Infect Dis Rep       Date:  2019-11-09       Impact factor: 3.725

Review 2.  Candida infections of the genitourinary tract.

Authors:  Jacqueline M Achkar; Bettina C Fries
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

3.  Profile of Candida albicans-secreted aspartic proteinase elicited during vaginal infection.

Authors:  Brad N Taylor; Peter Staib; Ayfer Binder; Antje Biesemeier; Miriam Sehnal; Martin Röllinghoff; Joachim Morschhäuser; Klaus Schröppel
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

4.  Cellular and molecular biology of Candida albicans estrogen response.

Authors:  Georgina Cheng; Kathleen M Yeater; Lois L Hoyer
Journal:  Eukaryot Cell       Date:  2006-01

5.  Her choice: dealing with lactobacilli, vaginitis, and antibiotics.

Authors:  Marie V Pirotta; Suzanne M Garland
Journal:  Curr Infect Dis Rep       Date:  2005-11       Impact factor: 3.725

6.  Fungal Profile of Vulvovaginal Candidiasis in a Tertiary Care Hospital.

Authors:  Krishnapriya Kalaiarasan; Rakesh Singh; Latha Chaturvedula
Journal:  J Clin Diagn Res       Date:  2017-03-01

7.  Comparing the Recurrence of Vulvovaginal Candidiasis in Patients Undergoing Prophylactic Treatment with Probiotic and Placebo During the 6 Months.

Authors:  Robab Davar; Fahimeh Nokhostin; Maryam Eftekhar; Leili Sekhavat; Mohammad Bashiri Zadeh; Farimah Shamsi
Journal:  Probiotics Antimicrob Proteins       Date:  2016-09       Impact factor: 4.609

8.  Vulvovaginal candida in a young sexually active population: prevalence and association with oro-genital sex and frequent pain at intercourse.

Authors:  E Rylander; A-L Berglund; C Krassny; B Petrini
Journal:  Sex Transm Infect       Date:  2004-02       Impact factor: 3.519

9.  Relative risk of vaginal candidiasis after use of antibiotics compared with antidepressants in women: postmarketing surveillance data in England.

Authors:  Lynda Wilton; Monika Kollarova; Emma Heeley; Saad Shakir
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

10.  Antibiotic-associated Vulvovaginal Candidiasis.

Authors:  Jinping Xu; Jack D. Sobel
Journal:  Curr Infect Dis Rep       Date:  2003-12       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.